The landscape of dementia prognosis has evolved dramatically with the arrival of subtle biomarkers, which includes amyloid PET scans, tau imaging, and blood-centered tests that could detect Alzheimer's pathology decades prior to signs or symptoms arise. While these technological improvements characterize remarkable progress in knowing neurodegenera